However, in the VICTORIA trial in patients with very high NT-proBNP, a lower benefit from vericiguat was observed whereas in GALACTIC-HF, omecamtiv mecarbil showed a trend toward more favorable effects in patients with higher rather than lower levels of NT-proBNP. 8.2.
← all excerpts
Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure.
1
—
—